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Abstract – A variety of potentially biologically active 1,2,3-triazoles, derived from 
(–)-menthol, lactic acid, D-glucose, oestrone, cholesterol, and phenacetin, have 
been synthesised through the multicomponent alkyne-azide 1,3-dipolar 
cycloaddition catalysed by copper nanoparticles on activated carbon in neat water.
 
INTRODUCTION 
Heterocycles play an important role in biochemical processes and, therefore, they are very frequently found 
as substructures in numerous pharmaceutical products.1 Among them, 1,2,3- and 1,2,4-triazoles are known 
to possess remarkable biological properties as antitumor, antiviral, anti-inflammatory, analgesic, antifungal 
or antibacterial agents.2 Nowadays, click chemistry3 represents a pivotal tool in the discovery of new 
therapeutic compounds and in medicinal chemistry since allows molecular diversity in a direct, precise and 
selective manner.4 In particular, the Huisgen 1,3-dipolar cycloaddition of azides and alkynes5 has become a 
synthetic cornerstone since the paramount discovery by the groups of Meldal6 and Sharpless7 of its 
copper(I)-catalysed version (CuAAC).8 This powerful methodology, which is considered the paradigm of a 
click reaction, gives a straight access into the 1,2,3-triazole moiety with high reliability and selectivity. This 
  
 
particular nucleus is used as a robust linker of complex and varied molecular architectures of significance in 
different fields, and especially in synthetic routes to bioactive molecules. 
On the other hand, owing to our dedication to study and understand the reactivity of active metals and 
nanoparticles,9 we found out that active copper [obtained from CuCl2·2H2O, metal lithium, and a catalytic 
amount of 4,4'-di-tert-butylbiphenyl (DTBB) in THF at room temperature] was able to reduce various 
functional groups under very mild conditions.10 We discovered that copper nanoparticles (CuNPs) were 
formed either from CuCl2·2H2O or anhydrous CuCl2 under the aforementioned conditions. These CuNPs 
(10 mol%) effectively catalysed the 1,3-dipolar cycloaddition of organic azides and terminal alkynes in 
remarkably short reaction times (10–120 min).11 Notwithstanding the superior catalytic activity when 
compared with other commercially available copper sources, the CuNPs underwent dissolution under the 
reaction conditions (Et3N, THF, 65 ºC) and could not be reused. In order to overcome this inconvenience, 
we turned our attention to the development of supported catalysts based on CuNPs, which might be 
endowed of better recyclability and stability than the unsupported counterparts.12 We also tried to take 
advantage of the multicomponent domino synthesis of heterocycles, as an atom- and time-efficient method 
to construct valuable molecules in a one-pot operation.13 In this sense, we introduced a catalyst consisting 
of oxidized copper nanoparticles on activated carbon, readily prepared under mild conditions, which 
manifested a high versatility in the multicomponent Huisgen 1,3-dipolar cycloaddition in water.14 Not only 
organic halides, but some other azide precursors, such as aryldiazonium salts, anilines, epoxides and one 
alkene, were proven to be appropriate substrates in this process. In order to expand the applicability of this 
methodology, we wish to present herein our results on the multicomponent synthesis of an array of 
1,2,3-triazoles, derived from some natural products and a synthetic one, with potential biological activity. 
RESULTS AND DISCUSSION 
The starting materials selected include the monoterpene alcohol (–)-menthol, methyl lactate, D-glucose 
pentaacetate, oestrone, cholesterol, and phenacetin. These compounds were properly derivatised prior to 
the click reaction by the introduction of a propargyl moiety or, in the case of D-glucose pentaacetate, by 
transformation into the bromo derivative. Except in the latter case, all the multicomponent reactions were 
carried out with sodium azide and benzyl bromide in water, using CuNPs/C as the catalyst, at a low metal 
loading (0.5 mol%). 
Menthol is the major component of peppermint and cornmint oils. The mint oils can be considered as a kind 
of life elixirs according to their endless list of applications as well as their pharmacological and biological 
activities including:15 (a) in vitro antimicrobial, antimalarial and antigiradial activities; (b) antiviral 
activities against Newcastle disease, herpes simplex, vaccinia, Semliki Forest, and West Nile viruses in egg 
and cell culture systems; (c) inhibitory activity against HIV-1 reverse transcriptase; (d) spasmolytic activity 
  
 
on smooth muscles of experimental animals; (e) effective in alleviating the symptoms of irritable bowel 
syndrome; (f) as a spasmolytic in non-ulcer dyspepsia; (g) acetylcholinesterase inhibition and reversible 
antifertility. Peppermint oil is used as carminative, antiseptic and local anesthetic in cold, cough, and other 
preparations. It has been recommended as an adjunct to colonoscopy to reduce the colonic spasm. In 
traditional medicine, it has been applied as analgesic, stomachic, stimulant, antiseptic, local anesthetic, 
antispasmodic (in treating indigestion, nausea, sore throat, diarrhea, colds, headaches, toothaches, and 
cramps), and as an antitumor agent. One of the most important applications of mints is as flavouring agents 
in food products; e.g. chewing gums, alcoholic and non-alcoholic beverages, desserts, meat, etc. More 
recently, it has been discovered that menthol inhibits melanoma growth and that, due to its low toxicity, 
might be used with benefit in the treatment of this devastating disease.16 
(–)-Menthol was the first substrate which was subjected to study under the conditions of our 
methodology.14 The multicomponent click reaction of propargyl menthyl ether 1 proceeded at 65 ºC to give, 
exclusively, the corresponding 1,2,3-triazole in good isolated yield (Scheme 1). The outcome of this 
reaction was similar to that previously found for phenyl propargyl ether, though rather slower.14 This 
heterocycle is new and it would be interesting to explore how the presence of the triazole unit can affect 
some of the multiple properties described above. 
 
 
Scheme 1 
 
Lactic acid occurs in sour milk as a result of lactic acid bacteria. It can be also found in molasses due to the 
partial conversion of sugars, in apples and other fruits, tomato juice, beer, wines, opium, ergot, foxglove, 
and several higher plants, especially during germination.17 L-lactate is produced in muscles during exertion 
and is a common additive in animal nutrition since its health promoting properties enhance the performance 
of farm animals. It is a good descaler, soap-scum remover, and is widely applied in household cleaning 
products. Lactic acid is used as a natural and environmentally safe anti-bacterial agent in disinfecting 
products as well as an additive in food and drinking water. We prepared the propargyl ether of racemic 
methyl lactate which nicely underwent the alkyne-azide cycloaddition in water, giving rise to triazole 4 in 
excellent yield (Scheme 2). Despite the CuAAC has been widely studied in proteomics and 
peptidomimetics, its application to hydroxy acids has been neglected.18 In fact, and to the best of our 
  
 
knowledge, lactic acid derivatives (either acids or esters) of the type 4, bearing the triazolylmethyl moiety, 
have not been reported hitherto. 
 
O
O
MeO
3
+ NaN3 +
0.5 mol% CuNPs/C
H2O, 70 ºC, 8 h
Ph Br O
O
MeO
N
NN
Ph
4
95%  
Scheme 2 
 
Glucose is a ubiquitous fuel in biology. It is used as an energy source in most organisms, from bacteria to 
humans. In the latter, glucose is a primary source of energy for the brain and hence its availability 
influences psychological processes. Glucose derivatives can also develop some patterns of biological 
action. For instance, it has been found that the two anomers of L-glucose pentaacetate stimulate insulin 
release and, therefore they could be used as novel insulinotropic tools in the treatment of 
non-insulin-dependent diabetes mellitus.19 The copper(I)-catalysed Huisgen cycloaddition has attracted the 
attention of carbohydrate synthetic chemists and glycobiologists in their efforts to clarify the role of 
carbohydrates in biological processes, as well as in the development of new therapeutics and vaccines.20 
Pentacetylated D-glucose modified at C-4 with a 1,2,3-triazoyl unit has recently displayed herbicidal 
activity in pre-emergence tests.21 In order to prepare a triazole derived from glucose, -D-glucose 
pentaacetate was transformed into the -D-glucopyranosyl bromide 5. The domino nucleophilic 
substitution at the anomeric position and dipolar cycloaddition required prolonged heating at a higher 
temperature, leading to the expected -D-glucopyranosyl triazole 6 in 70% isolated yield with inversion of 
the configuration (Scheme 3). To the best of our knowledge, there is only one method in the literature that 
reports the one-pot synthesis of 6.22 This method, which is fast and mild, cannot be considered a 
multicomponent but a sequential process, as the azide is generated prior to the 1,3-dipolar cycloaddition. 
 
 
Scheme 3 
 
Oestrone is an oestrogenic hormone secreted by the ovary as well as by the adipose tissue. It occurs in 
pregnancy, postmenopausal women, urine of women and mares, in follicular liquor of many animals, in 
  
 
human placenta, in the urine of bulls and in palm-kernel oil.23 Oestrogens have key roles in the development 
and maintenance of normal sexual and reproductive function. Although traditionally presumed to be a 
female hormone, oestrone also exerts a vast range of biological effects in the cardiovascular, skeletal, 
immune, and central nervous systems.24 In addition to the physiological role of oestrone, it can induce 
tumors in various organs of several laboratory animal species. The aryl propargyl ether moiety in modified 
oestrone 7 exhibited very near behaviour to that of the simpler phenyl propargyl ether in the 
CuNPs/C-catalysed dipolar cycloaddition, as regards both reaction time (8 vs. 7 h) and isolated yield (76 vs. 
81%) (Scheme 4). In contrast with the oestrogen 17-ethynyloestradiol, for which the synthesis of the 
corresponding triazoles was accomplished by us11 and other groups, compound 8 represents the first 
triazolyl derivative of oestrone ever synthesised. 
 
 
Scheme 4 
 
Cholesterol is the principal sterol in the higher animals. It can be found in all body tissues, especially in the 
brain, spinal cord, and in animal fats or oils. It is used to produce hormones, bile acids, vitamin D, cell 
membranes and is transported in the blood plasma of all mammals.25 Although cholesterol is important and 
necessary for mammals, high levels of cholesterol in the blood can damage arteries and are potentially 
linked to diseases such as those associated with the cardiovascular system. It has also been found to play an 
important role in myelin biogenesis and myelin disease.26 A very recent study reveals that 
2'-triazolyl-2-deoxyuridines with a cholesterol moiety anchor in biocompatible phospholipid membranes 
without affecting the order in the double layers, thus demonstrating that the membranes can be equipped 
with nucleobases through this approach.27 Following our multicomponent approach, a new cholesterol 
derivative 10, with a pendant triazolylmethyl unit, was synthesised in good yield under the standard 
conditions (Scheme 5). It is noteworthy that, both the reaction time and yield are akin to those noted for 
(–)-menthol, as in these two examples a cyclohexyl propargyl ether moiety is involved. 
 
  
 
 
Scheme 5 
 
Phenacetin is a synthetic analgesic and antipyretic introduced in 1887, and widely used until the third 
quarter of the twentieth century.28 However, it is no longer used in therapy because of its toxicity. The FDA 
ordered the withdrawal of drugs containing phenacetin in November 1983, owing to its carcinogenic and 
kidney-damaging properties.29 In this case, we modified the starting material by anchoring the propargyl 
substituent to the nitrogen of the acetamido group. Under the CuNPs/C catalysis, a new triazole 12 was 
produced in high isolated yield after 8 h (Scheme 6). We must point out that the reactivity shown by 11 was 
near identical to that observed for N-propargylphthalimide in our previous study (i.e., 8 h, 84% yield), 
under the same reaction conditions.14 Only the corresponding biological/pharmacological studies will 
unveil whether compound 12 has the same deleterious effects as phenacetin or improved therapeutical 
properties. 
 
 
Scheme 6 
 
In conclusion, we have demonstrated that the multicomponent click synthesis of 1,2,3-triazoles, catalysed 
by copper nanoparticles on activated carbon in water, is an adequate and direct method to prepare 
potentially biologically active compounds. A series of new heterocyclic compounds, derived from the 
natural products (–)-menthol, lactic acid, D-glucose, oestrone, and cholesterol, and from the synthetic 
compound phenacetin, have been prepared in 70–95% yield. The reactivity of the starting materials 
  
 
resembles that of simpler propargyl derivatives possessing the same structural features. The possible 
biological activity of the new triazoles will be tested in a near future. 
EXPERIMENTAL 
Melting points were obtained with a Reichert Thermovar apparatus. Optical rotations were measured with a 
Perkin-Elmer 341 polarimeter with a thermally jacketted 5 cm cell at approximately 20 ºC. Concentrations 
(c) are given in g/100 ml and [] values are given in units of 10–1 deg cm2 g–1. Infrared analysis was 
performed with a Jasco 4100LE (Pike MIRacle ATR) spectrophotometer; wavenumbers are given in cm–1. 
NMR spectra were recorded on Bruker Avance 300 and 400 spectrometers (300 and 400 MHz for 1H NMR; 
75 and 100 MHz for 13C NMR); chemical shifts are given in () parts per million and coupling constants (J) 
in Hertz. The retention times and mass spectra (EI) were obtained at 70 eV on an Agilent 5973 spectrometer 
connected to a HP 6890 gas chromatograph, equipped with a HP-5MS 30 m capillary column (0.25 mm 
diameter, 0.25 m film thickness), using helium (1 mL/min) as carrier gas, Tinjector = 270 ºC, Tcolumn = 60 ºC 
(3 min) and 60–270 ºC (15 ºC/min); retention times (tR) are given in min, fragment ions in m/z with relative 
intensities (%) in parenthesis. HRMS analyses were carried out on a Finnigan MAT95S spectrometer. 
Starting materials. Anhydrous copper(II) chloride (Aldrich), lithium powder (MEDALCHEMY S. L.), 
DTBB (4,4'-di-tert-butylbiphenyl, Aldrich), activated charcoal (Norit CA1, Aldrich), and sodium azide 
(Across) were commercially available. All the starting materials and other reagents were commercially 
available of the best grade (Aldrich, Acros, Alfa Aesar) and were used without further purification. THF 
was dried in a Sharlab PS-400-3MD solvent purification system using an alumina column. Propargylation 
of the substrates was done following a literature procedure.30 Tetra-O-acetyl-α-D-glucopyranosyl bromide 
5 was synthesised from D-glucose pentaacetate according to a literature procedure.31 
(1S,2S,5R)-Menthyl propargyl ether (1): All the physical and spectroscopic data were in agreement with 
those reported in the literature.30 
(±)-Methyl 2-(prop-2-ynyloxy)propanoate (3): yellow liquid; tR 5.00; Rf 0.85 (hexane/EtOAc 4:1); IR 
3274, 2928, 2857, 1732, 1456, 1275, 1202, 1125, 1072, 1031 cm–1; 1H NMR (300 MHz, CDCl3) δ 1.44 (d, 
J = 6.9 Hz, 3H), 2.47 (t, J = 2.4 Hz, 1H), 3.76 (s, 3H), 4.19, 4.34 (2dd, J = 16.1, 2.4 Hz, 2H), 4.27 (q, J = 6.9 
Hz, 1H); 13C NMR (CDCl3) δ 18.35, 51.89, 56.96, 72.87, 74.98, 78.77, 172.98; MS m/z 142 (M+, 1), 88 (16), 
83 (100), 59 (11), 55 (17). HRMS (EI) m/z Calcd for C7H10O3: 142.0630. Found: 142.0638. 
Tetra-O-acetyl-α-D-glucopyranosyl bromide (5): All the physical and spectroscopic data were in 
agreement with those reported in the literature.31 
O-Propargyloestrone (7): white solid; mp 140.8–143.0 ºC; tR 23.62; Rf 0.57 (hexane/EtOAc 4:1); IR 3295, 
2916, 2865, 2160, 1732, 1604, 1497, 1308, 1286, 1260, 1223, 1024, 819, 694, 644 cm–1; 1H NMR (300 
MHz, CDCl3) δ 0.91 (s, 3H), 1.35–1.72 (m, 6H), 1.90–2.58 (m, 8H), 2.85–2.96 (m, 2H), 4.66 (d, J = 2.4 Hz, 
  
 
2H), 6.71 (d, J = 2.4 Hz, 1H), 6.79 (dd, J = 8.4, 2.7 Hz, 1H), 7.22 (d, J = 8.4 Hz, 1H); 13C NMR (CDCl3) δ 
13.82, 21.56, 25.85, 26.48, 29.62, 30.91, 31.55, 35.84, 38.26, 43.96, 50.38, 55.70, 75.31, 78.77, 112.32, 
114.93, 126.34, 132.96, 137.85, 155.52, 220.85; MS m/z 309 (M++1, 22), 308 (M+, 100), 307 (48), 223 (17), 
210 (12), 209 (11), 207 (19), 197 (12), 184 (20), 183 (22), 181 (11), 169 (12), 152 (10), 128 (15), 115 (14), 
55 (11). HRMS (EI) m/z Calcd for C21H24O2: 308.1776. Found: 308.1778. 
O-Propargylcholesterol (9): All the physical and spectroscopic data were in agreement with those 
reported in the literature.32 
N-(4-Ethoxyphenyl)-N-(prop-2-yn-1-yl)acetamide (11): yellow liquid; tR 13.47; Rf 0.58 (hexane/EtOAc 
1:1); IR 3290, 2980, 2931, 1657, 1508, 1477, 1422, 1389, 1288, 1244, 1222, 1044, 922, 840, 738, 642, 623 
cm–1; 1H NMR (300 MHz, CDCl3) δ 1.44 (t, J = 6.9 Hz, 3H), 1.85 (s, 3H), 2.21 (t, J = 2.5 Hz, 1H), 4.06 (q, 
J = 6.9 Hz, 2H), 4.44 (d, J = 2.5 Hz, 2H), 6.93, 7.19 (AA'BB' system, J = 8.7, 4H); 13C NMR (CDCl3) δ 
14.60, 22.15, 38.14, 63.55, 71.80, 79.15, 115.08, 128.97, 134.62, 158.58, 170.32; MS m/z 217 (M+, 60), 175 
(59), 174 (10), 147 (21), 146 (100), 136 (10), 108 (28), 91 (10), 80 (16). HRMS (EI) m/z Calcd for 
C13H15NO2: 217.1103. Found: 217.1097. 
Typical procedure for the preparation of CuNPs/C: Anhydrous copper(II) chloride (135 mg, 1 mmol) 
was added to a suspension of lithium (14 mg, 2 mmol) and 4,4'-di-tert-butylbiphenyl (DTBB, 27 mg, 0.1 
mmol) in THF (2 mL) at room temperature under an argon atmosphere. The reaction mixture, which was 
initially dark blue, rapidly changed to black, indicating that the suspension of CuNPs was formed. This 
suspension was diluted with THF (18 mL) followed by the addition of the activated carbon (1.28 g). The 
resulting mixture was stirred for 1 h at room temperature, filtered, and the solid successively washed with 
water (20 mL), THF (20 mL) and dried under vacuum. 
General procedure for the CuNPs/C-catalysed click reaction. NaN3 (72 mg, 1.1 mmol), the bromide (1 
mmol), and the alkyne (1 mmol) were added to a suspension of CuNPs/C (20 mg, 0.5 mol% Cu) in H2O (2 
mL). The reaction mixture was warmed to 70 ºC and monitored by TLC and/or GLC until total conversion 
of the starting materials. Water (30 mL) was added to the resulting mixture, followed by extraction with 
EtOAc (3 × 10 mL). The collected organic phases were dried with anhydrous MgSO4 and the solvent was 
removed in vacuo to give the corresponding triazoles, which were purified by recrystallisation in EtOAc. 
1-Benzyl-4-[(1R,2S,5R)-menthyloxymethyl]-1H-1,2,3-triazole (2): white solid; mp 46.4–48.0 ºC; tR 
19.95; Rf 0.66 (hexane/EtOAc 3:2); [α]D20 –64.5 (c 1.0, CHCl3); IR 3056, 2911, 2867, 2845, 1455, 1218, 
1123, 1085, 1070, 1052, 762, 726, 718, 698 cm–1; 1H NMR (400 MHz, CDCl3) δ 0.60 (d, J = 7.2 Hz, 3H), 
0.84, 0.91 (2d, J = 6.6 Hz, 6H), 0.79–0.96 (m, 2H), 1.14–1.42 (m, 3H), 1.54–1.68 (m, 2H), 2.05–2.19 (m, 
2H), 3.17 (dt, J = 10.4, 4.4 Hz, 1H), 4.55, 4.74 (2d, J = 12.6 Hz, 2H), 5.51 (s, 2H), 7.23–7.30 (m, 2H), 
7.32–7.41 (m, 3H), 7.44 (s, 1H); 13C NMR (CDCl3) δ 16.02, 20.90, 22.25, 23.20, 25.22, 31.41, 34.43, 40.16, 
48.09, 54.06, 61.88, 78.66, 122.16, 128.03, 128.64, 129.00, 134.61, 146.58; MS m/z 327 (M+, 1), 190 (16), 
  
 
188 (23), 174 (11), 173 (72), 144 (30), 95 (21), 91 (100), 83 (10), 81 (19), 69 (11), 67 (12), 55 (17). HRMS 
(EI) m/z Calcd for C20H29N3O: 327.2311. Found: 327.2315. 
(±)-Methyl 2-[(1-benzyl-1H-1,2,3-triazol-4-yl)methoxy]propanoate (4): yellow liquid; tR 16.95; Rf 0.23 
(hexane/EtOAc 3:2); IR 2987, 2951, 1742, 1497, 1455, 1208, 1120, 1066, 1048, 1030, 755, 720, 698 cm–1; 
1H NMR (300 MHz, CDCl3) δ 1.40 (d, J = 6.9 Hz, 3H), 3.71 (s, 3H), 4.13 (q, J = 6.9 Hz, 1H), 4.61, 4.74 (2d, 
J = 12.3 Hz, 2H), 5.51 (s, 2H), 7.22–7.30 (m, 2H), 7.32–7.41 (m, 3H), 7.56 (s, 1H); 13C NMR (CDCl3) δ 
18.33, 51.70, 53.85, 63.19, 73.94, 122.58, 127.88, 128.46, 128.82, 134.34, 144.69, 173.15; MS m/z 275 (M+, 
1), 188 (55), 144 (25), 91 (100), 65 (10). HRMS (EI) m/z Calcd for C14H17N3O3: 275.1270. Found: 
275.1286. 
1-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-4-phenyl-1H-1,2,3-triazole (6): All the physical and 
spectroscopic data were in agreement with those reported in the literature.22 
O-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]oestrone (8): white solid; mp 151.9–154.9 ºC; Rf 0.51 
(hexane/EtOAc 1:1); [α]D20 +88.0 (c 1.0, CHCl3); IR 2924, 1734, 1612, 1578, 1453, 1279, 1256, 1245, 
1160, 1065, 1048, 1005, 818, 731, 722, 710, 691 cm–1; 1H NMR (300 MHz, CDCl3) δ 0.90 (s, 3H), 
1.35–1.74 (m, 6H), 1.89–2.29 (m, 5H), 2.33–2.59 (m, 2H), 2.80–2.95 (m, 2H), 5.16 (s, 2H), 5.53 (s, 2H), 
6.71 (d, J = 2.7 Hz, 1H), 6.77 (dd, J = 8.7, 2.7 Hz, 1H), 7.24–7.31 (m, 3H), 7.34–7.40 (m, 3H), 7.51 (s, 1H); 
13C NMR (CDCl3) δ 13.82, 21.55, 25.85, 26.47, 29.60, 31.53, 35.84, 38.27, 43.94, 47.97, 50.37, 54.21, 
62.11, 112.35, 114.74, 122.47, 126.36, 128.10, 128.77, 129.11, 132.62, 134.43, 137.84, 144.85, 156.22, 
220.92; MS m/z 441 (M+, 27), 270 (14), 145 (13), 144 (91), 115 (10), 91 (100). HRMS (EI) m/z Calcd for 
C28H31N3O2: 441.2416. Found: 441.2418. 
O-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]cholesterol (10): white solid; mp 110.1–113.4 ºC; Rf 0.38 
(hexane/EtOAc 7:3); [α]D20 –17.1 (c 1.0, CHCl3); IR 3087, 2933, 2864, 1457, 1438, 1377, 1365, 1332, 1220, 
1985, 1052, 1023, 799, 721, 700 cm–1; 1H NMR (300 MHz, CDCl3) δ 0.70 (s, 3H), 0.89 (dd, J = 6.6, 1.2 Hz, 
6H), 0.94 (d, J = 6.6 Hz, 3H), 1.01 (s, 3H), 0.83–1.72 (m, 22H), 1.79–2.08 (m, 5H), 2.21–2.31 (m, 1H), 
2.35–2.47 (m, 1H), 3.23–3.41 (m, 1H), 4.68 (s, 2H), 5.36 (d, J = 5.7 Hz, 1H), 5.53 (s, 2H), 7.27–7.33 (m, 
2H), 7.36–7.42 (m, 2H), 7.47 (s, 1H); 13C NMR (CDCl3) δ 11.83, 18.69, 19.33, 21.03, 22.54, 22.80, 23.79, 
24.26, 27.99, 28.21, 31.86, 31.91, 35.76, 36.16, 36.81, 37.14, 38.99, 39.50, 39.75, 42.29, 50.13, 54.14, 
56.12, 56.73, 61.69, 77.20, 78.97, 121.79, 122.15, 128.16, 128.72, 129.08, 134.57, 140.65, 146.40; MS m/z 
557 (M+, 1), 368 (13), 191 (12), 190 (100), 91 (35). HRMS (EI) m/z Calcd for C37H55N3O2: 557.4345. 
Found: 557.4337. 
N-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]-N-(4-ethoxyphenyl)acetamide (12): pale yellow solid; mp 
83.6–85.6 ºC; tR 21.17; Rf 0.30 (hexane/EtOAc 3:7); IR 3065, 2979, 2940, 1649, 1509, 1395, 1288, 1243, 
1224, 1046, 840, 736, 723, 704 cm–1; 1H NMR (300 MHz, CDCl3) δ 1.41 (t, J = 6.9 Hz, 3H), 1.82 (s, 3H), 
4.00 (q, J = 7.2 Hz, 2H), 4.85 (s, 2H), 5.49 (s, 2H), 6.83, 6.99 (AA'BB' system, J = 8.7, 4H), 7.19–7.26 (m, 
  
 
2H), 7.31–7.40 (m, 3H), 7.55 (s, 1H); 13C NMR (CDCl3) δ 14.60, 22.38, 44.70, 53.89, 60.19, 115.05, 
123.25, 127.81, 128.47, 128.80, 128.87, 134.61, 135.45, 144.57, 158.25, 170.66; MS m/z 350 (M+, 21), 309 
(11), 308 (50), 109 (14), 108 (17), 91 (100), 65 (15). HRMS (EI) m/z Calcd for C20H22N4O2: 350.1743. 
Found: 350.1733. 
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